Rachel Salazar

Rachel Salazar

Company: Bicara Therapeutics

Job title: Vice President, Head of Programs & Portfolio


BCA101, A Novel Dual-Action Antibody Combining the Precision Targeting of EGFR with the Immunomodulating Power of TGF-β 10:30 am

Download the full event guide for session detailsRead more

day: Track B - Day 1 AM

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.